Weekly Analysts’ Ratings Changes for Seaport Therapeutics (SPTX)

A number of firms have modified their ratings and price targets on shares of Seaport Therapeutics (NASDAQ: SPTX) recently:

• 10/14/2026 – Seaport Therapeutics was given a new $28.00 price target by Seaport Research Partners.
• 10/14/2026 – Seaport Therapeutics is now covered by Canaccord Genuity Group. They set a “buy” rating and a $28.00 price target on the stock.
• 10/8/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by UBS Group.
• 10/8/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 9/25/2026 – Seaport Therapeutics was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/25/2026 – Seaport Therapeutics was given a new $46.00 price target by Seaport Research Partners.
• 9/25/2026 – Seaport Therapeutics is now covered by Raymond James Financial. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 9/25/2026 – Seaport Therapeutics is now covered by Raymond James Financial. They set a “strong-buy” rating and a $46.00 price target on the stock.
• 9/10/2026 – Seaport Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for central nervous system (CNS) disorders. The company uses its Glyph platform, a technology designed to create prodrugs that may improve the delivery, tolerability, and effectiveness of certain therapies, including treatments intended to reach the brain.

Seaport’s pipeline includes investigational therapies for neurological and neuropsychiatric conditions. Its programs have included GTX-102, an oral investigational medicine being developed for Angelman syndrome, a rare genetic neurodevelopmental disorder, as well as additional candidates aimed at addressing unmet needs in CNS care.

The company was established with support from PureTech Health and is headquartered in Boston, Massachusetts.